Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02224898
Recruitment Status : Completed
First Posted : August 25, 2014
Last Update Posted : November 17, 2015
Sponsor:
Information provided by (Responsible Party):
Walter G. Park, M.D., M.S., Stanford University

Brief Summary:

The research objective of this pilot study is to test the feasibility of a mobile electronic mindfulness therapy service for patients with definite or suspected chronic pancreatitis.

A secondary aim will be to determine the effect of the intervention on a symptom severity/global assessment of improvement for patients with chronic pancreatitis. The investigators hypothesize that a one-month period of daily mindfulness therapy delivered via a phone messaging service will reduce symptoms.


Condition or disease Intervention/treatment
Pancreatitis, Chronic Behavioral: Mobile Mindfulness Therapy

Detailed Description:

Patients who meet diagnostic criteria for definite or suspected chronic pancreatitis and have current symptoms over the past month will be considered for study enrollment. Potential patients will be initially pre-screened by a patient chart review.

If not excluded during the pre-screening process, potential subjects will be mailed questionnaires to fill out at home and speak with a member of the research team for an intake interview. At that time, they will be asked to sign a consent form after its review. Subjects will then be given instructions on how to participate in daily mindfulness therapy for one-month via the phone messaging service with a research team member.

The total duration of the study intervention will be four weeks where enrolled patients will be asked to perform daily mindfulness sessions through our electronic mobile mindfulness therapy service.

Patients will be sent a daily automated text message or call reminder to their mobile phone at a pre-determined time, selected by the patient at the intake interview. The text message will prompt patients with a phone number to call to access the Mindfulness Therapy sessions.

When the patient is ready, s/he will call the provided phone number which is an automated answering and voice messaging service, which will prompt the patient to select a mindfulness therapy session of varying durations from 2 to 30 minutes. The session will lead the patients through deep relaxation breathing exercise for the duration the patient selected from the phone menu. Although the investigators will only ask patients to do one mindfulness session a day, patients are free to do as many as they want a day. At the end of their session, patients will leave a voice message with their name and current location such as home or work. The investigators will track the mindfulness sessions the individual patient participated in by obtaining their recorded voice messages in an inbox that correlates with the duration of the mindfulness session that the patient participated in. The voice messaging system will also provide information of the time the voice message was left, or time of completion of the patient's mindfulness session. If the patient prematurely terminated his/her session, got disconnected from his/her session or forgot to leave a message, the patient may call the same provided phone number to leave a message with his/her name, date of unrecorded session along with its duration and location of participation such as home or work.

At the end of the study at four weeks, patients will be asked to complete an exit interview. The patient will be asked to fill out questionnaires during this interview. The patient will also be asked to participate in an informal exit interview with one of the research team members. Patients will be asked of any new medications were added during the duration of the study. They will also be asked regarding any changes in chronic pancreatitis strategies and any new stressors.


Layout table for study information
Study Type : Observational
Actual Enrollment : 18 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis
Study Start Date : August 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Group/Cohort Intervention/treatment
Definite/Suspected Chronic Pancreatitis
Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
Behavioral: Mobile Mindfulness Therapy
Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.

Healthy Control Group
Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
Behavioral: Mobile Mindfulness Therapy
Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.




Primary Outcome Measures :
  1. Feasibility of a Mobile Mindfulness Therapy Application for Chronic Pancreatitis [ Time Frame: 1 month ]
    The primary outcome will measure daily compliance rates with the denominator being 30 days and the numerator equal to the number of days out of 30 that the patient used the mobile mindfulness therapy application.


Secondary Outcome Measures :
  1. The effect of mobile mindfulness therapy on a symptom severity/global assessment of improvement for patients with definite or suspected chronic pancreatitis [ Time Frame: 1 month ]
    After consent to participate, the patient will complete a set of quality of life instruments before participating in the mindfulness therapy sessions. After 30 days, the patient will repeat completing the set of quality of life instruments. These include the SF-36, PANQOLI, and specific PROMIS QoL instruments.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We will recruit a minimum of 10 and maximum of 40 subjects diagnosed with chronic pancreatitis and 5 healthy control subjects with no past or present chronic gastrointestinal symptoms lasting greater than 8 weeks, no chronic medical conditions and no organic gastrointestinal disease. All patients with suspected/definite chronic pancreatitis will be associated with Stanford Hospital and Clinics and the 5 healthy controls may or may not be associated with Stanford.
Criteria

Inclusion Criteria:

  • For the study group: Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging.
  • For the control group: no history of chronic GI symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and not be currently experiencing gastrointestinal symptoms.
  • Age 18 to 80
  • Willing to give informed consent
  • Able to complete entire study
  • Ability to speak and read English
  • Regular menstrual cycles or menopause for at least 6 months
  • Owns a mobile phone with texting capabilities
  • Unlimited minutes and text messaging dataplan for mobile phone
  • Physically and mentally capable of using a mobile phone
  • Phone access

Exclusion Criteria:

  • Red flags of concern: anemia, blood in stools, unexplained weight loss, unexplained fevers
  • Pregnant or nursing woman, or planning on becoming pregnant within next year
  • Travel plans outside of the county over the study duration or a month prior
  • Change in medications one month prior or during study
  • Change in chronic pancreatitis management strategies one month prior or during study such as dietary changes, exercise, counseling and behavioral therapies.
  • Current co-morbid condition that might account for GI symptoms
  • Current infectious diseases: HIV, Hepatitis A, B or C, other
  • Psychiatric Conditions: moderate to severe depression (ECT, unable to work, disrupts ADL's), moderate to severe anxiety (unable to work, disrupts ADL's), bipolar disorder, schizophrenia, or history of psychosis, suicidal ideation or attempt, substance abuse (alcohol and/or drugs in past year), dissociative disorder, dementia related disorder
  • Immunologic Diseases: systemic lupus, moderate to severe arthritis, scleroderma, other
  • Gastrointestinal Disorders: inflammatory bowel diseases (ulcerative colitis, Crohn's), celiac disease,personal history of colon cancer or polyps, other unless condition associated with chronic pancreatitis.
  • Cardiovascular disorder, clinically significant in past 12 months
  • Pain disorder, clinically significant (back pain, fibromyalgia)
  • Recent surgery, during 6 months prior to study enrollment or during study period (except minor surgeries such as wisdom teeth extraction, cataract surgery, corrective lens surgery, and/or minor skin surgeries)
  • Major stressor(s) in life 3 months prior to study or anticipated over the next month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02224898


Locations
Layout table for location information
United States, California
Stanford Hospital and Clinics
Palo Alto, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Walter Park, MD Stanford Hospital

Layout table for additonal information
Responsible Party: Walter G. Park, M.D., M.S., Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT02224898     History of Changes
Other Study ID Numbers: IRB-30976
First Posted: August 25, 2014    Key Record Dates
Last Update Posted: November 17, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Pancreatitis, Chronic
Pancreatic Diseases
Digestive System Diseases